CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive Gain (Loss)
Beginning Balance at Dec. 31, 2022	$ 490,151	$ 6	$ 878,884	$ (383,790)	$ (4,949)
Shares, Outstanding, Beginning Balance at Dec. 31, 2022		55,039,380
Exercise of stock options	2,163		2,163
Exercise of stock options, Shares		276,692
Vesting restricted stock, Shares		34,764
Issuance of shares under employee stock purchase plan	962		962
Issuance of shares under employee stock purchase plan, Shares		39,423
Stock-based compensation expense	20,565		20,565
Unrealized loss on marketable securities	1,547				1,547
Net loss	(79,727)			(79,727)
Ending Balance at Jun. 30, 2023	435,428	$ 6	902,574	(463,517)	(3,635)
Shares, Outstanding, Ending Balance at Jun. 30, 2023		55,390,259
Beginning Balance at Mar. 31, 2023	462,005	$ 6	889,755	(424,718)	(3,038)
Shares, Outstanding, Beginning Balance at Mar. 31, 2023		55,276,226
Exercise of stock options	676		676
Exercise of stock options, Shares		67,987
Vesting restricted stock, Shares		6,623
Issuance of shares under employee stock purchase plan	962		962
Issuance of shares under employee stock purchase plan, Shares		39,423
Stock-based compensation expense	11,181		11,181
Unrealized loss on marketable securities	(597)				(597)
Net loss	(38,799)			(38,799)
Ending Balance at Jun. 30, 2023	435,428	$ 6	902,574	(463,517)	(3,635)
Shares, Outstanding, Ending Balance at Jun. 30, 2023		55,390,259
Beginning Balance at Dec. 31, 2023	394,971	$ 6	926,269	(530,752)	(552)
Shares, Outstanding, Beginning Balance at Dec. 31, 2023		55,585,305
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs	301,373		301,373
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs, shares		3,884,158
Issuance of common stock through At-The Market Sales Agreement, net of issuance costs of $1.2 million		1,519,453
Issuance of common stock through at-the market sales agreement, net of issuance costs	48,740		48,740
Exercise of stock options	4,562		4,562
Exercise of stock options, Shares		355,339
Vesting restricted stock, Shares		163,903
Issuance of shares under employee stock purchase plan	1,135		1,135
Issuance of shares under employee stock purchase plan, Shares		64,225
Stock-based compensation expense	26,309		26,309
Unrealized loss on marketable securities	(1,314)				(1,314)
Net loss	(90,619)			(90,619)
Ending Balance at Jun. 30, 2024	684,924	$ 6	1,308,388	(621,371)	(2,099)
Shares, Outstanding, Ending Balance at Jun. 30, 2024		61,572,383
Beginning Balance at Mar. 31, 2024	711,203	$ 6	1,292,283	(579,309)	(1,777)
Shares, Outstanding, Beginning Balance at Mar. 31, 2024		61,353,146
Exercise of stock options	630		630
Exercise of stock options, Shares		74,318
Vesting restricted stock, Shares		80,694
Issuance of shares under employee stock purchase plan	1,134		1,134
Issuance of shares under employee stock purchase plan, Shares		64,225
Stock-based compensation expense	14,341		14,341
Unrealized loss on marketable securities	(322)				(322)
Net loss	(42,062)			(42,062)
Ending Balance at Jun. 30, 2024	$ 684,924	$ 6	$ 1,308,388	$ (621,371)	$ (2,099)
Shares, Outstanding, Ending Balance at Jun. 30, 2024		61,572,383